



# DIAGNOS

Your Knowledge Partner

**PRESS RELEASE**

OTCQB: DGNOF  
TSXV : ADK  
SOURCE : DIAGNOS Inc.

2017.12.19

## DIAGNOS Successfully Passed ISO Annual Surveillance Audit

Brossard, Quebec, Canada – December 19, 2017 - DIAGNOS Inc. (“DIAGNOS”, “the Corporation” or “we”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its **FLAIRE** platform based on Artificial Intelligence (**AI**), announces today that it has successfully passed the ISO 13485 - Medical devices and ISO 9001 annual surveillance audit for its CARA healthcare platform.

"As part of the requirements for the commercialization of the CARA healthcare platform from Health Canada, the Food and Drug Agency in the US and CE in Europe, our Quality Management System is subject to thorough statutory annual compliance audits. I would like to take this opportunity to thank our employees involved in quality management for their commitment and hard work", said Mr. André Larente, President of DIAGNOS.

### About DIAGNOS and its technologies

DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging, text and traditional data mining. DIAGNOS has developed its own Artificial Intelligence (“AI”) technologies, CARA and **FLAIRE**. **FLAIRE** is a powerful AI engine that provides the capability of analyzing large and complex data sets. Using Deep Learning methodology combined with our own proprietary algorithms we can deploy rapidly new solutions to the healthcare market

Additional information on DIAGNOS is available at [www.diagnos.ca](http://www.diagnos.ca) and [www.sedar.com](http://www.sedar.com).

For further information, please contact:

Mr. André Larente, President  
DIAGNOS Inc.  
Tel: 450-678-8882 ext. 224  
[alarente@diagnos.ca](mailto:alarente@diagnos.ca)

Daniel Renaud or Thomas Renaud, Managing Directors  
Arrowhead Business and Investment Decisions, LLC  
Tel: +1 212 619 6889, ext. 7010  
[diagnos@arrowheadbid.com](mailto:diagnos@arrowheadbid.com)

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*